Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Satellos Bioscience's accounts receivables for the quarter that ended in Mar. 2026 was C$0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Satellos Bioscience's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was C$4.30.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Satellos Bioscience's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Satellos Bioscience's accounts receivable are only considered to be worth 75% of book value:
Satellos Bioscience's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Satellos Bioscience Accounts Receivable Related Terms
Satellos Bioscience Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Satellos Bioscience's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of C$0.00 Mil mean?
Satellos Bioscience (TSX:MSCL) has a Accounts Receivable of C$0.00 Mil as of Mar. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Satellos Bioscience and its competitors.
Is Satellos Bioscience's Accounts Receivable too high?
Satellos Bioscience's current Accounts Receivable is C$0.00 Mil. Overall, Satellos Bioscience has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Satellos Bioscience's Accounts Receivable compare to VRTX and REGN?
Satellos Bioscience's Accounts Receivable of C$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Satellos Bioscience and its competitors. Satellos Bioscience's current Accounts Receivable is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Satellos Bioscience stock overvalued right now?
Satellos Bioscience (TSX:MSCL) has a current Accounts Receivable of C$0.00 Mil. The current Accounts Receivable is C$0.00 Mil. Satellos Bioscience's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Satellos Bioscience (TSX:MSCL), the current Accounts Receivable is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
37GF Score
Get the complete analysis for TSX:MSCL
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MSCL has been successfully added to your 
